Conservative treatment in early stage endometrial cancer: a review

Giuseppe Trojano¹, Claudiana Olivieri¹, Raffaele Tinelli², Gianluca Raffaello Damiani³, Antonio Pellegrino⁴, Ettore Cicinelli⁵

¹ Department of Obstetrics and Gynecology AOU Policlinico University Hospital Bari, Italy; ² Department of Obstetrics and Gynecology Perrino Hospital ASL Brindisi, Italy; ³ Department of Obstetrics and Gynecology Camberlingo Hospital ASL Brindisi, Italy; ⁴ Department of Obstetrics and Gynecology ASST-Lecco, Manzoni Hospital, Lecco, Italy

Summary. Endometrial Cancer (EC) is the commonest gynecological cancer and its incidence is increasing. The diagnosis of endometrial carcinoma in young women of childbearing age is rare. Indeed, only 4% of patients with endometrial carcinoma are <40 years of age. It’s typically diagnosed in postmenopausal women. The standard approach for the management of endometrial cancer in young women of childbearing age is hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy but is not ideal for women interested in future fertility. We reviewed the published literature to clarify in fertile women who have not yet fulfilled their desire for motherhood, what are the strategies, the risks of a conservative treatment of early stage of Endometrial Cancer and what are the obstetric outcomes in these patients. Recently, several studies have reported encouraging results on fertility-sparing management of EC with high dose of progestins in selected women associated or not with hysteroscopic resection. (www.actabiomedica.it)

Key words: endometrial cancer, fertility sparing surgery, conservative treatment, hysteroscopic resection uterine preservation

Introduction

Endometrial cancer (EC) is one of the most common gynecological cancers. More than 90% of cases of endometrial cancer occur in perimenopause women and 25% are premenopausal (1, 2). However, 4% of women with endometrial cancer are younger than 40 years old and over 70% of them are nulliparous at diagnosis, due to the fact that in the current era women delay their childbearing. The majority of endometrial cancers are diagnosed early stage (80% in stage I), with 5-year survival rates over 95%. Most endometrial cancer cases are sporadic, with only 10% considered familiar.

Endometrial carcinoma has been classified into two main clinic-pathological and molecular types: Type I and Type II.

Type I is the endometrioid type (EEC) (3) because it’s similar to the endometrium and is characterized by genetic predisposition (eg. Lynch syndrome–LS), such as obesity, polycystic ovarian syndrome (PCOS), ano-ovulatory cycles, irregular menstruation that causes hyper estrogenic state, that is a main predisposing factor for developing Type I EC. Type I EC has a favorable outcome due to minimal myometrium invasion (4).

Type II cancers are associated with higher patient age, high stage and grade, non-endometrioid histology, and poor prognosis, instead. It includes several subtypes such as serous, clear cell and undifferentiated carcinomas (5).

Most patients with endometrial cancer have an excess of estrogen and typically show a characteristic clinical profile: high body mass index (BMI) that is considered as overweight (BMI 25–30) or obese (BMI 30), often with other components of metabolic syndrome (hypertension, diabetes) (6). This is the most commonly identified risk factor because obesity is associated...
associated with peripheral estrogen conversion via aromatization in adipose tissue (7, 8). Nulliparity and infertility are classical risk factors for endometrial cancer. Other risk factors include unopposed estrogen therapy, estrogen-producing tumors such as ovarian granulose, theca cell tumors and early menarche/late menopause. Studies also show that exposure to tamoxifen increases the risk of endometrial cancer-related estrogen as well as an unbalanced hormone replacement therapy (9). Only endometrial carcinoma type I may be subject to a fertility sparing treatment.

Materials and methods

We performed a Pubmed, Medline search of articles published in English between 1959 and 2018 with the key words 'Endometrial cancer', ‘fertility sparing surgery’, ‘conservative treatment’, 'hysteroscopic resection' and 'uterine preservation’. Moreover, we identified several articles from bibliographies of these publications including case reports, case series, original articles, review articles, and meta-analyses, with the purpose of analyzing the different methods of treatment reproductive outcomes and follow-up after fertility sparing treatment in women with an early stage of EC.

Selection of patients: stage, grade and histopathology

When considering a conservative management approach, we should consider clinical and pathological characteristics of the tumor for can select the appropriate medical intervention. A conservative management approach could be considered in patients: <40 years old (relative indication), have to intent to preserve fertility and plan to conceive as soon as possible after remission, with no contraindication for medical treatment and with a histological diagnosis of grade I endometrial carcinoma; histotype: endometrioid with positive hormone receptor (type I), tumor diameter <2.0 cm, stage IA without myometrial and adnexal involvement, negative lymph-vascular space invasion (LVSI) and diffuse immunohistochemical expression of progesterone receptors on endometrial biopsy. These patients are considered as "low risk" population. According to Gynecologic Oncology Group (GOG) and Federation International of Gynecologic and Obstetric (FIGO), the most important prognostic factors (10) for lymph node metastasis in patients with EC were the grade of tumor and the depth of myometrial invasion with the risk of involvement less than 1% and excellent 5-year progression-free survival of 95% if the tumor is grade 1 with an overall survival of 90%. In the absence of risk factors, a conservative approach to surgical staging is feasible, safe and not associated with an increase in cancer-related mortality (11).

Diagnosis

Diagnosis should be performed by Hysteroscopy and endometrial biopsy (12, 13). The Society of Gynecologic Oncology (SGO) recommends that the preferred tissue formats include curettage and biopsy and that devices that result in crushed, cauterized, or very small samples are unacceptable (14). Imaging performed by MRI or Transvaginal Ultrasound by experts, helpful to detect possible myometrial invasion and exclude synchronous ovarian tumor or suspicious lymph-adenopathy. Seems that MRI is slightly more sensitive than ultrasound for the evaluation of myometrial invasion and that the implementation of both techniques increase sensitivity (15-16).

Selection of drug, dose, length of treatment

The standard treatment for EC is a hysterectomy with bilateral salpingo-oophorectomy, with or without lymph node dissection with pelvic washing, sometimes combine with adjuvant chemotheray or radiotherapy is necessary. Although this is a highly effective approach, carrying a 5-year survival rate of 93%, it also results in a permanent loss of reproductive potential which is often unacceptable to younger women who wish to preserve their fertility. Therefore, selected patients with EC, are candidates for a conservative approach (2). Hence, fertility-sparing treatment with progestin is a good compromise for these women. Recently, hysteroscopic resection in addition to hormonal therapy followed by pregnancies in young women have been reported (17, 18).
Medical treatment

Conservative management of EC is based principally on medical treatment with oral progestins. Medical treatment Hormonal therapy, alone or in a combination with hysteroscopic ablation. Progestins (19, 20) are medroxyprogesterone acetate or megestrol acetate. Although today there is no consensus on the optimal dosage or duration of treatment, it appears that 62-75% of these women respond well to progestational treatment and the absence of progesterone receptors (PR), can make inhomogeneous the success of progestin treatment (2, 21). First Kistner in 1959 (22) to use for EC a progesterone formulation using various dosing strategies. Another method of treatment is Levonorgestrel-releasing IUD (23-25), removing the IUD when patients are ready to attempt pregnancy. With or without GnRH analogues, or a combination of IUD and oral progesterone (26). With a high response rates in patients with grade I EC, despite some patients with prior progesterone treatment.

Surgical treatment by hysteroscopy

Mazzon et al (17) reported a series of patient treated with hysteroscopic resection of tumor with resection of the adjacent endometrial margins and the myometrium underlying the tumor with biopsies of uterine cavity and under general anesthesia followed by oral therapy with progestin, Megestrol acetate (160 mg daily) or Medroxyprogesterone acetate (400 mg/ day), beginning the fifth day after the surgery and continuing for six months (27). Other authors describe the use of IUD for 12 months. Shan et al. instead performed hysteroscopy curettage during which resected the major part of tumor tissue, later followed by complete endometrial resection with hysteroscopy. Marton et al. performed an initial polypectomy resulted in the diagnosis of carcinoma. One month later performed a complete endometrial ablation (29). Park et al (28, 29) described the possible adverse effects of hysteroscopy resection prior to hormone therapy with an increase in adhesive syndrome after resection. This can influence the obstetric outcome.

Follow-up

In order to assess response, hysteroscopy and imaging at 6 months must be performed and not before. If no response is achieved after 6 months, standard surgical treatment should be performed. In case of complete response, conception must be encouraged and referral to a fertility clinic is recommend. Maintenance treatment should be considered in responders who wish to delay pregnancy. Patients not undergoing hysterectomy should be re-evaluated clinically every 6 months. After completion of childbearing, a hysterectomy and salpingo-oophorectomy should be recommended (30, 31). The preservation of ovary can be considered depending on age and genetic risk factors. Hence, the follow-up of these patients under conservative treatment in the first year included serial transvaginal Ultrasonography (TV-US) every three months. A computed tomography scan (CAT) six months after surgery is recommended. Several authors performed check-ups with only TV-US or in association with CAT scans, every six month starting from the second years. A strictly follow-up during the period treatment is recommended (21, 32). Hysterectomy should be recommended as the definitive treatment for patients with persistent disease. The need for bilateral salpingo-oophorectomy depends on the risk factor and therefore this possibility must be discussed with the patient. Patients who after 6 months of treatment have a partial response could be offered continuation of treatment for another 3 to 6 months.

A recent study concerning the use of antidiabetic drug metformin and its effect on EC cells has shown that metformin suppresses EC cell growth (associated with the reduction of the proliferation marker Ki-67) (33, 34) and have an anti-proliferative effect in women with EC and insulin resistance or PCOS (35). In the future a treatment could be possible in association with progestin and active weight management early stage of EC (36).

In premenopausal women who are obese, the use of aromatase inhibitors in adjunct to oral proges- terone, initially Megestrol acetate 160 mg/day for 6 months subsequently as second treatment after second biopsy with persistent atypical hyperplasia or Grade I endometrioid endometrial cancer is added to Meges-
trole acetate 160 mg/day Anastrozole 1mg/day for 6 months or intrauterine device for 8 months if at the second biopsy the result was Grade III endometrioid endometrial cancer (37, 38), seems like a reasonable therapeutic option, as they have a significant proportion of their estrogen production coming from peripheral conversion in adipose tissue. Agorastos et al. in 2005 (39), demonstrate that aromatase inhibitors reduce endometrial thickness in patients who cannot be subjected to hysterectomy.

Strategies of fertility preservation

One of the strategies to preserve fertility is oocyte cryopreservation. Patients with previous history of infertility or other risk factors for infertility should be encouraged to use of assisted reproductive techniques. Reassuring data confirm the safety of Assisted Reproduction Techniques (ART) (40). Ovulation induction does not appear to be associated with increased risk of relapse, and subsequent pregnancies do not worsen oncological outcomes (41-43).

Outcomes

Primary outcomes are the evaluation of complete response to therapy, defined as the absence of disease on subsequent endometrial biopsy; we define partial response if the disease was downgraded to complex atypical hyperplasia. No response, defined as who have no evidence of response and progression is defined the presence of a higher grade of cancer on biopsy. Secondary outcomes are obstetrical outcomes (44, 45).

Pregnancy rate described in literature for exclusively hormonal treatment is between 35-60%, but after a combined treatment, hysteroscopic and hormonal pregnancy rate increases to about 70%. The recurrence rate of EC after conservative treatment is between 30-40% in from 4 to 66 months (44, 46, 47) and can be offered a re-treatment with progestin.

The mortality associated with conservative treatment of early stage of EC is very low despite the fact that the rate of recurrence is high (48).

Conclusion

Uterine preservation is a safe and feasible option in select young women who have not yet fulfilled their desire for motherhood with stage IA low-grade progesterone receptor positive endometrioid tumors with no metastatic involvement or risk factors. An adequate evaluation and a correct diagnosis by expert physician confirming the absence of myometrial invasion. The treatment of choice is progestin associated or not to hysteroscopy with a monitoring for long periods. Hysteroscopic surgery prior to hormone therapy may improve the rate of recurrence when the resection margins are free, although serve further studies. Individualization of care is important as each patient has different characteristics as well as different needs and expectations.

Conflict of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

1. Zivanovic O, Carter J, Kauff ND, et al. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 2009; 115: 504-9.
2. Carneiro MM, Lamaita RM, Ferreira MC, et al. Fertility-preservation in endometrial cancer: is it safe? Review of the literature JBRA Assist Reprod V 20 no 4 2016.
3. Cicchillitti L, Corrado G, Carosi M, et al. Lamin A as novel molecular prognostic biomarker for EC. It J Gynaecol Obstet 2016, 28: N. 2.
4. Bogani G, Dowdy SC, Cliby WA, et al Management of endometrial cancer: issues and controversies. Eur J Gynaecol Oncol 2016; 37: 6-12.
5. Caponio MA, Addati T, Popescu O, et al. P16INK4a protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: Diagnostic and clinical consideration. CancerBiomarkers 2014; 14: 169-175.
6. Lasalandra C, Coviello M, Falco G, et al. Serum Vascular Endothelial Growth Factor and Adiponectin Levels in Patients with Benign and Malignant Gynecological Disease. International Journal of Gynecological Cancer 2010; 20(4).
7. Nagle CM, Marquart L, Bain CJ, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer 2013; 49: 2717-2726.
8. Corzo C, Santillan NB, Shannon N, Westin, Ramirez P,
Conservative treatment in early stage endometrial cancer. JMIG, 2017. J Minim Invasive Gynecol 2018; 25(2): 308-313.

9. Committee opinion 601-2014 reaffirmed 2017 ACOG Topic-oxifen and Uterine cancer.

10. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016; 387: 1094-1108.

11. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009; 27: 1214-9.

12. Trojano G, Damiani GR, Casavola VC et al. The Role of Hysteroscopy in Evaluating Postmenopausal Asymptomatic Women with Thickened Endometrium. Gynecol Minim Invasive Ther 2018; 7(1): 6-9.

13. Loiacono RM, Trojano G, Del Gaudio N, et al. Hysteroscopy as a Valid Tool for Endometrial Pathology in Patients with Postmenopausal Bleeding or Asymptomatic Patients with a Thickened Endometrium: Hysteroscopic and Histological Results. Gynecol Obstet Invest 2015; 79: 210-216.

14. Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120: 1160-1175.

15. Frei KA, Kinkel K, Bonel HM, Lu Y, Zaloudek C, Hricak H. Prediction of deep myometrial invasion in patients with EC: clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis. Radiology 2000; 216: 444-449.

16. Rodolakis A, Biliatis I, Morice P et al. European Society of Gynecological Oncology Task Force for Fertility Preservation Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer 2015; 25: 1258-1265.

17. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage 1A endometrial carcinoma for fertility preservation. Fertil Steril 2010; 93: 1286-1289.

18. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol 2017; 28: e2.

19. Gonthier C, Walker F, Luton D, Yazbeck C, Madelelat P, Koskas M. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol 2014; 133: 33-7.

20. Pal N, Broaddus RR, Urbauer DL et al. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia with the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 2018; 0: 1-8.

21. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 2015; 20: 270-8.

22. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959; 12: 1106-1122.

23. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-482.

24. Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and welldifferentiated early endometrial carcinoma in young women. Ann Oncol 2011; 22: 643-9.

25. Laurelli G, DiVagno G, Scafa C, Losito S, Del Giudice M, Greggi S. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol 2011; 120: 43-6.

26. Colombo N, Creutzberg C, Amant F et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up, International Journal of Gynecological Cancer 2016; 27(1): 2-30.

27. Casadio P, Guasina F, Paradisi R, Leggieri C, Caprara G Seracchioli R. Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study The Oncologist 2018; 23: 1-3.

28. Park H, Seong SJ, Yoon BS. The effect of operative hysterectomy conducted before progestins treatment in early stage endometrial cancer from the view of fertility Gynecol Oncol 2011; 123(2): 427-8.

29. Alonso S, Castellanos T, Lapuente F, Chiva L. Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature ecancer 2015; 9: 505.

30. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Leventhal C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review. Gynecol Oncol 2004; 95: 133-138.

31. Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 2010; 20: 1170-1187.

32. Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. Int J Gynecol Cancer 2015; 25: 1010-4.

33. Kim SR, van der Zanden C, Ikiz H, Kuzeljovic B, Havelock J, Kwon JS, Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer from a Population-Base Study J Obstet Gynaeoc Can 2017.

34. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998; 4: 2779-85.

35. La Russa M, Zapardiel I, Halaska MJ, et al Conservative management of endometrial cancer: a survey amongst European clinicians. Archives of Gynecology and Obstetrics 2018.

36. Hawkes AL, Quinn M, Gebski V, et al. Improving treatment for obesewomen with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine de-
vice + Metformin + weight loss in EC (feMME) trial. Contemp Clin Trials 2014; 39: 14Y21.

37. Straubhar A, Soisson AP, Dodson M, Simons E. Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone. Gynecologic Oncology Reports 2017; 21: 10-12.

38. Burnett A, Bahador A, Amexcua C. Anastrozole, an aromatase inhibitor, and medoxyprogesterone acetate therapy, in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. Gynecol Oncol 2004; 94: 832-834.

39. Agorastos T, Vaitis V, Pantazis Efthathiadis E, Vavilis D, Bontis J. 2005. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005; 118: 239-240.

40. Tong XM, Lin XN, Jiang HF, Jiang LY, Zhang SY, Liang FB. Fertility-sparing treatment and pregnancy outcomes in the early stage of endometrial carcinoma. Chin med J 2013; 126(15): 2965-2971.

41. Matthews ML, Hurst BS, Marshburn PB, Usadi RS, Papadakis MA, Sarantou T. Cancer, fertility preservation, and future pregnancy: a comprehensive review. Obstet Gynecol Int 2012; 2012: 953-937.

42. Fujimoto A, Ichinose M, Harada M, Hirata T, Osuga Y, Fujii T. The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer. J Assist Reprod Genet 2014; 31: 1189-94.

43. Zapardiel I, Cruz M, Diestro MD et al. Assisted reproductive techniques after fertility-sparing treatments in gynecological cancers. Hum Reprod Update 2016; 22: 281-305.

44. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207(4): 266.e1–12.

45. Rodolakis A, Biliatis I, Morice P, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer 2015; 25: 1258-1265.

46. Tangjitgamol S, Manusirivithaya S, Hanprasertpong J. Fertility sparing in EC. Gynecol Obstet Invest 2009; 67: 250-268.

47. ParkJY, KimDY, KimJH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progesterin for young women with EC (KGOG 2002). Eur J Cancer 2013; 49: 868-874.

48. Chifumi Ohaygi-Hara Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature, 2015; 291(1): 151-157.

Received: 4 November 2018
Accepted: 7 February 2019
Correspondence: Gianluca Raffaello Damiani
Department of Obstetrics and Gynecology, University of Bari, Bari, Italy
Tel. +390805612443
Fax +390805478928
E-mail: damiani14@alice.it